Evidence map›Paper›PMID 30771244›Full record

ArticleCancer science2019

Enrichment of CLDN18-ARHGAP fusion gene in gastric cancers in young adults.

Izuma Nakayama, Eiji Shinozaki, Seiji Sakata, Noriko Yamamoto, Junko Fujisaki, Yusuke Muramatsu, Toru Hirota, Kengo Takeuchi, Shunji Takahashi, Kensei Yamaguchi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 2 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. The Significance of theFrontiers in oncology · 2020
    Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Therapeutic strategy for scirrhous type gastric cancer.Japanese journal of clinical oncology · 2025
    Review
  9. Review
  10. Review
  11. Survival outcomes of patients with gastric cancer treated with first-line nivolumab plus chemotherapy based on claudin 18.2 expression.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2025
    Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Early gastric cancer with RhoGAP fusion is linked to frequent nodal metastasis and a part of microtubular-mucocellular histology.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024
    Article
  17. Review
  18. Article
  19. Claudin 18.2 as a novel therapeutic target.Nature reviews. Clinical oncology · 2024
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Izuma NakayamaDepartment of Oncotherapeutic Medicine, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Eiji ShinozakiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Seiji SakataPathology Project for Molecular Targets, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Noriko YamamotoDivision of Pathology, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Junko FujisakiDepartment of Gastroenterology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Yusuke MuramatsuDepartment of Gastroenterology, Kobari General Hospital, Chiba, Japan.
Toru HirotaDivision of Cellular and Molecular Imaging of Cancer, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Kengo TakeuchiPathology Project for Molecular Targets, Cancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Shunji TakahashiDepartment of Oncotherapeutic Medicine, Graduate School of Medicine, Tohoku University, Sendai, Japan.
Kensei YamaguchiDepartment of Gastroenterological Chemotherapy, Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuo NodaCancer Institute of the Japanese Foundation for Cancer Research, Tokyo, Japan.
Japanese Foundation For Cancer Research · JPTohoku University · JPKobari General Hospital · JP

Funding

Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports and Technology of Japan
6 · The paper itself

Abstract

Gastric cancer in young adults has been pointed out to comprise a subgroup associated with distinctive clinicopathological features, including an equal gender distribution, advanced disease, and diffuse-type histology. Comprehensive molecular analyses of gastric cancers have led to molecular-based classifications and to specific and effective treatment options. The molecular traits of gastric cancers in young adults await investigations, which should provide a clue to explore therapeutic strategies. Here, we studied 146 gastric cancer patients diagnosed at the age of 40 years or younger at the Cancer Institute Hospital (Tokyo, Japan). Tumor specimens were examined for Helicobacter pylori infection, Epstein-Barr virus positivity, and for the expression of mismatch repair genes to indicate microsatellite instability. Overexpression, gene amplifications, and rearrangements of 18 candidate driver genes were examined by immunohistochemistry and FISH. Although only a small number of cases were positive for Epstein-Barr virus and microsatellite instability (n = 2 each), we repeatedly found tumors with gene fusion between a tight-junction protein claudin, CLDN18, and a regulator of small G proteins, ARHGAP, in as many as 22 cases (15.1%), and RNA sequencing identified 2 novel types of the fusion. Notably, patients with the CLDN18-ARHGAP fusion revealed associations between aggressive disease and poor prognosis, even when grouped by their clinical stage. These observations indicate that a fusion gene between CLDN18 and ARHGAP is enriched in younger age-onset gastric cancers, and its presence could contribute to their aggressive characteristics.

Indexed as

Gene Expression Regulation, NeoplasticAdolescentAdultClaudinsFemaleGene AmplificationGene Expression ProfilingGTPase-Activating ProteinsHelicobacter InfectionsHumansImmunohistochemistryIn Situ Hybridization, FluorescenceKaplan-Meier EstimateMaleNeoplasm MetastasisNeoplasm StagingClaudinsCLDN18 protein, humanGTPase-Activating ProteinsOncogene Proteins, Fusiondiffuse typegenomeHelicobacter pylorirearrangementstomach

Identifiers

PMID30771244
PMCPMC6447833
OpenAlexW2914467196

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.